Purification and partial characterization of a megakaryocyte colony-stimulating factor from human plasma

Megakaryocytic colony formation (CFU-Meg) in essential thrombocythemia: quantitative and qualitative abnormalities of bone marrow CFU-Meg

For the purpose of examining the mechanisms for the overproduction of megakaryocytes and platelets in essential thrombocythemia (ET), marrow megakaryocytic colony-forming units (CFU-Meg) were characterized using a methylcellulose culture system in nine patients with ET, and they were compared with those of 16 control subjects and four patients with secondary thrombocytosis (ST). The number of CFU-Meg per 10(5) cells in ET was significantly higher (p less than .001) than that in the controls (5.8 times of the controls) or that in ST. ET showed endogenous CFU-Meg (58 +/- 16% of the total CFU-Meg) that could form megakaryocytic colonies without phytohemagglutinin-stimulated leukocyte-conditioned medium (PHA-LCM) as a source of Meg-CSA. The controls and the patients with St revealed no endogenous CFU-Meg. The dose-response studies with PHA-LCM revealed that CFU-Meg from ET are highly sensitive to low concentrations of PHA-LCM compared to CFU-Meg from the control and ST. Erythropoietic burst-forming units (BFU-E) were monitored as a control progenitor, because the patients with ET studied did not have erythrocytosis. Although five out of nine patients with ET had endogenous BFU-E, the percentages of endogenous BFU-E were small (4-10%). The number of BFU-E in ET was not different from the control value. Thus, ET is associated with an enlarged CFU-Meg compartment that shows abnormal growth patterns when cultured in vitro, while the growth abnormality of BFU-E is small, which may underlie the hematological features of ET. The culture of CFU-Meg should be clinically useful for differentiating ET from ST.

Biomolecule-cell interactions and the regulation of myelopoiesis

The regulation of myelopoiesis in vivo most likely entails a complex set of interactions between cell-derived biomolecules and their target cells. Much of what we currently know of these interactions has been derived from studies in vitro utilizing techniques for the purification of both the biomolecules and the cells producing and responding to these factors. Stimulating and suppressing influences have been uncovered, and with the cloning and purification of biologically active factors, studies assessing the actions of these molecules in vivo have begun. From studies in vitro it is apparent that many of the purified molecules can have move than one action and that different molecules can collaborate in a synergistic manner to enhance or suppress functional endpoints.

Studies of human megakaryocytopoiesis using an anti-megakaryocyte colony-stimulating factor antiserum

We produced an antiserum by immunizing rabbits with purified human megakaryocyte colony stimulating factor (Meg-CSF). With the use of an anti-Meg-CSF IgG fraction (AM-IgG), we detected immunoreactive Meg-CSF both in human aplastic anemia serum (AAS) and normal serum. Based on our immunological and biological analyses, Meg-CSF appeared to be antigenically as well as functionally distinct from human urinary erythropoietin (EPO) and thrombopoietic stimulating factor. The AM-IgG fraction was able to suppress the ability of both aplastic anemia serum and purified Meg-CSF to promote megakaryocyte colony formation. In addition, the supernatant formed after immune precipitation of the AAS with AM-IgG no longer possessed Meg-CSF-like activity. The AM-IgG did not suppress the ability of EPO, phytohemagglutinin-stimulated leukocyte conditioned medium (PHA-LCM), or PHA-LCM + EPO to promote erythroid, granulocyte-macrophage, or mixed colony formation, respectively. The use of this antibody has further defined the dependency of human megakaryocytopoiesis on Meg-CSF.